2022 American Transplant Congress » Kidney Immunosuppression
Date: Tuesday, June 7, 2022
Time: 3:30pm-5:00pm
Location: Hynes Room 302
Session Type: Rapid Fire Oral Abstract
Meeting: 2022 American Transplant Congress
- 3:30pm-3:40pm
Long Term Follow-Up of a Phase 2 Clinical Trial to Induce Tolerance in Living Donor Kidney Transplant Recipients
- 3:40pm-3:50pm
Five-Year Follow-Up from a Prospective, Randomized Trial of Belatacept-Based, CNI Free/Early Steroid Withdrawal Regimens
- 3:50pm-4:00pm
Real-Life Tacrolimus Levels Are Associated with Biopsy-Proven Acute Rejection After the First Year Post-Kidney Transplantation
- 4:00pm-4:10pm
Validation of the iBox Surrogate End Point in CNI Free, Belatacept Treated Patients (BENEFIT & BENEFIT-EXT)
- 4:10pm-4:20pm
De-Novo Belatacept Therapy is Associated with an Increased Risk of Invasive CMV Disease After Kidney Transplantation
- 4:20pm-4:30pm
Long-Term Outcomes After Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant: A Matched Cohort Study
« View all sessions from the 2022 American Transplant Congress